Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of high dose opioids and sedatives on survival in terminally ill cancer patients
Autore:
Morita, T; Tsunoda, J; Inoue, S; Chihara, S;
Indirizzi:
Seirei Mikatabara Hosp, Seirei Hosp, Hamamatsu, Shizuoka 4338558, Japan Seirei Mikatabara Hosp Hamamatsu Shizuoka Japan 4338558 ka 4338558, Japan
Titolo Testata:
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
fascicolo: 4, volume: 21, anno: 2001,
pagine: 282 - 289
SICI:
0885-3924(200104)21:4<282:EOHDOA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
SYMPTOM CONTROL; MIDAZOLAM; HOSPICE; MANAGEMENT; DELIRIUM; CHLORPROMAZINE; HALOPERIDOL; PREDICTION; INFUSION; LIFE;
Keywords:
advanced cancer palliative care; sedation sedative; opioid; survival;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Morita, T Seirei Mikatabara Hosp, Seirei Hosp, 3453 Mikatabaracho, Hamamatsu, Shizuoka 4338558, Japan Seirei Mikatabara Hosp 3453 Mikatabaracho Hamamatsu Shizuoka Japan 4338558
Citazione:
T. Morita et al., "Effects of high dose opioids and sedatives on survival in terminally ill cancer patients", J PAIN SYMP, 21(4), 2001, pp. 282-289

Abstract

Concerns that high dose opioids anti sedatives might shorten patient survival could contribute to insufficient symptom alleviation for terminally illcancer patients. To examine the effects of opioids and sedatives prescribed in the final 48 hours on Patient survival, a re-analysis of the prospectively collected data was performed on 209 hospice on patients. Patient characteristics and clinical symptoms were prospectively recorded, and information about the use of opioids and sedatives in the last two days was collected by a chart review. Opioids were prescribed in 82% of the patients, with amedian dose of 80 mg oral morphine equivalent (OME)/48 hours. Sixty percent received some sedative medications, mainly haloperidol (43 % of total sample 7.5/mg48 hours), midazolam (23%, 23mg/48 hours), and hydroxyzine (15%, 50 mg/48 hours). There were no significant differences in survival between the Patients who received different doses of opioids (<240, 240-599, and <greater than or equal to>600mg OME/48 hours) and of benzodinzepines (0, 1-59and greater than or equal to 60 mg parental midazolam equivalent/48 hours). Also, the survival of patients with haloperidol, hydroxyzine, and other sedative medications did not differ from those without. Furthermore, an addition of use of opioids and sedatives in the final 48 hours into the multiple regression model or survival prediction achieved no significant increase in predictability. In conclusion, opioids and sedatives used for symptom control in the last days are not associated with Patient survival. They are safe and useful medications to palliate severe distress in the terminal stage of cancer when administered with a low initial dosage and adequate titration. J Pain Symptom Manage 2001;21:282-289. (C) U.S. Cancer Pain Relief Committee, 2001.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 09:22:50